Stock Research for XXII

XXII

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

XXII Stock Chart & Research Data

The XXII chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the XXII chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


XXII Due diligence Resources & Stock Charts

The XXII stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View XXII Detailed Price Forecast - CNN Money CNN View XXII Detailed Summary - Google Finance
Yahoo View XXII Detailed Summary - Yahoo! Finance Zacks View XXII Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View XXII Trends & Analysis - Trade-Ideas Barrons View XXII Major Holders - Barrons
NASDAQ View XXII Call Transcripts - NASDAQ Seeking View XXII Breaking News & Analysis - Seeking Alpha
Spotlight View XXII Annual Report - CompanySpotlight.com OTC Report View XXII OTC Short Report - OTCShortReport.com
TradeKing View XXII Fundamentals - TradeKing Charts View XXII SEC Filings - Bar Chart
WSJ View Historical Prices for XXII - The WSJ Morningstar View Performance/Total Return for XXII - Morningstar
MarketWatch View the Analyst Estimates for XXII - MarketWatch CNBC View the Earnings History for XXII - CNBC
StockMarketWatch View the XXII Earnings - StockMarketWatch MacroAxis View XXII Buy or Sell Recommendations - MacroAxis
Bullish View the XXII Bullish Patterns - American Bulls Short Pains View XXII Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View XXII Stock Mentions - StockTwits PennyStocks View XXII Stock Mentions - PennyStockTweets
Twitter View XXII Stock Mentions - Twitter Invest Hub View XXII Investment Forum News - Investor Hub
Yahoo View XXII Stock Mentions - Yahoo! Message Board Seeking Alpha View XXII Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for XXII - SECform4.com Insider Cow View Insider Transactions for XXII - Insider Cow
CNBC View XXII Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for XXII - OTC Markets
Yahoo View Insider Transactions for XXII - Yahoo! Finance NASDAQ View Institutional Holdings for XXII - NASDAQ


Stock Charts

FinViz View XXII Stock Insight & Charts - FinViz.com StockCharts View XXII Investment Charts - StockCharts.com
BarChart View XXII Stock Overview & Charts - BarChart Trading View View XXII User Generated Charts - Trading View




Latest Financial News for XXII


If You Had Bought 22nd Century Group (NYSEMKT:XXII) Stock A Year Ago, You'd Be Sitting On A 50% Loss, Today
Posted on Wednesday January 22, 2020

It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...


22nd Century Group Appoints New Director and New Chairman
Posted on Monday January 13, 2020

Williamsville, NY, Jan. 13, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced the appointment of Roger O’Brien as a new member of 22nd Century Group’s Board of Directors (the “Board”) and the appointment of Nora Sullivan, an existing director of the Board, as the new Chairman of the Board.


22nd Century Group to Present its Modified Risk Tobacco Product Application to FDA’s Tobacco Products Scientific Advisory Committee
Posted on Monday December 23, 2019

Williamsville, NY, Dec. 23, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco and hemp/cannabis research, announced today that the U.S. Food and Drug Administration's (FDA) Tobacco Products Scientific Advisory Committee (TPSAC) will conduct a public hearing on Friday, February 14, 2020, regarding 22nd Century Group’s Modified Risk Tobacco Product (MRTP) application for its VLNC cigarettes under the proposed brand name of VLN® cigarettes. “We welcome the opportunity to publicly present our MRTP application and detail the science and evidence supporting the reduced exposure claims for VLN® cigarettes,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.


FDA Authorizes Marketing of 22nd Century Group’s Proprietary Moonlight® and Moonlight® Menthol Cigarettes
Posted on Tuesday December 17, 2019

Williamsville, NY, Dec. 17, 2019 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company that is a leader in tobacco harm reduction, Very Low Nicotine Content (VLNC) tobacco, and hemp/cannabis plant research, announced today that the U.S. Food and Drug Administration (FDA) has found that the marketing of 22nd Century Group’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes are “appropriate for the protection of the public health,” and the FDA has issued marketing orders to permit the sale of these products in the U.S. This FDA authorization follows the FDA’s review of the Premarket Tobacco Product Applications (PMTA) previously submitted by 22nd Century Group. “FDA authorization of 22nd Century’s proprietary Moonlight® and Moonlight® Menthol brand cigarettes is a major milestone in our efforts to drive meaningful change in the tobacco industry,” said Michael Zercher, President and Chief Operating Officer of 22nd Century Group.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.